ALCAM and colorectal cancer: Despite this adverse effect and similarity to each marker alone, the prognostic value of this combination of CD166 and CD44s did not contribute independent prognostic information in multivariable analysis, indicating no added benefit in risk stratification for patients with colorectal cancer in this series when evaluating double negativity compared with single negativity and effect on outcome.